• Publications
  • Influence
Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia.
STUDY OBJECTIVES Long-duration (> or = 6 months) polysomnographic studies of insomnia medications are lacking. This study evaluated the long-term efficacy of ramelteon, a selective MT1/MT2Expand
  • 120
  • 7
Sleep microstructure around sleep onset differentiates major depressive insomnia from primary insomnia
In the present study we investigate whether alterations of sleep propensity or of wake propensity are implicated in sleep initiation disturbances encountered in major depressive insomnia and inExpand
  • 65
  • 6
Effects of prolonged‐release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers
Melatonin is an important regulator of the sleep–wake cycle. A prolonged‐release formulation of melatonin (PR‐M) that essentially mimics the profile of the endogenous production of the hormone isExpand
  • 101
  • 5
  • PDF
Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia
Abstract Objective: To compare the hypnotic effects of a single dose of a sublingual formulation of zolpidem (Edluar) 10 mg vs oral formulation (Ambien) 10 mg by polysomnography (PSG) in DSM-IVExpand
  • 16
  • 2
Effect of short-term treatment with gaboxadol on sleep maintenance and initiation in patients with primary insomnia.
STUDY OBJECTIVE To perform an early evaluation of the efficacy and safety of gaboxadol in the treatment of primary insomnia. METHODS 26 adults (18-65 years) with DSM-IV criteria for primaryExpand
  • 45
  • 1
Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
OBJECTIVE The authors assessed the efficacy, safety, and tolerability of MIN-101, a compound with affinities for sigma-2 and 5-HT2A receptors and no direct dopamine affinities, in comparison withExpand
  • 32
  • 1
Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia
RationaleGaboxadol is a selective extrasynaptic GABAA agonist, previously in development for the treatment of insomniac patients.ObjectiveTo evaluate the acute efficacy and safety of gaboxadol inExpand
  • 31
Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial.
OBJECTIVE Current dopamine-blocking antipsychotic drugs have little impact on the cognitive deficits associated with schizophrenia. We evaluated whether MIN-101, a molecule that combines sigma-2Expand
  • 10
Pharmacokinetic profile of SKP‐1041, a modified release formulation of zaleplon
Two investigations aimed to define the pharmacokinetic profile of a modified‐release preparation of zaleplon (SKP‐1041).
  • 3